Release details

2016-01-08 07:00 CET
  • Print
  • Share Share

TiGenix participates in key conferences in the first half of 2016

Leuven (BELGIUM) - January 8, 2016, 7:00h CET - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the key conferences in which it is going to participate during the first half of 2016.

25-27January
Phacilitate Cell & Gene Therapy World, Washington, USA
Presenter (to be confirmed): Marie-Paule Richard, Chief Medical Officer

16-19 March
11th Congress of ECCO (European Crohn's and Colitis Organisation, Amsterdam, The Netherlands
Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief Financial Officer; Wilfried Dalemans, Chief Technical Officer; Marie-Paule Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialisation

22 March
4th Annual Regen Med Investor Day, New York, USA
Presenter: Eduardo Bravo, Chief Executive Officer

22 March
KBC Securities Benelux Biotech & Healthcare Conference,
Brussels, Belgium
Participant: Claudia D'Augusta, Chief Financial Officer

2-4 April
ACC: American College of Cardiology,
Chicago, USA
Participant (to be confirmed): Marie-Paule Richard, Chief Medical Officer

4-6 April
BIO-Europe Spring,
Stockholm, Sweden
Participant: Miguel Mulet, Director of Strategy and New Projects

6-7 April
Kempen & Co Healthcare & Life Sciences,
Amsterdam, Netherlands
Participant: Claudia D'Augusta, Chief Financial Officer

6-8 April
DIA - 28th Annual EuroMeeting, Hamburg, Germany
Participants: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

6-7 April
ARM's EU Advanced Therapies Summit, Stockholm, Sweden
Participants: Eduardo Bravo, Chief Executive Officer; Wilfried Dalemans, Chief Technical Officer;

25-27 April
Stem Cell Summit 2016, Boston, USA
Participants (to be confirmed): Eduardo Bravo, Chief Executive Officer

12-13 May
12th Symposium on stem cell therapy and cardiovascular innovations, Madrid, Spain
Participants: Marie-Paule Richard, Chief Medical Officer; Miguel Mulet, Director of Strategy and New Projects

18-20 May
World Stem Cells & Regenerative Medicine, London, UK
Participants: Eduardo Bravo, Chief Executive Officer; Miguel Mulet, Director of Strategy and New Projects

21-24 May
Digestive Disease Week, San Diego-California, USA
Participants: Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialization

6-9 June
BIO International Convention, San Francisco, USA
Participant: Miguel Mulet, Director of Strategy and New Projects

7-8 June
PDA: Advanced Therapy Medicinal Products, Berlin, Germany
Participants: Wilfried Dalemans, Chief Technical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

For more information, please contact:
TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).

Forward-looking information
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this press release. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

HUG#1977348